Study Finds Rituximab Equally Effective as Standard Treatment for EGPA

A recent study published in the Annals of Internal Medicine indicates that rituximab, a medication often used for treating various autoimmune conditions, does not demonstrate superior efficacy compared to conventional treatment strategies for eosinophilic granulomatosis with polyangiitis (EGPA).

Conducted by a team led by Dr. Benjamin Terrier at Hôpital Cochin in Paris, the research involved a phase 3, multicenter trial aimed at determining the effectiveness of rituximab in inducing remission in patients diagnosed with EGPA. The study enrolled individuals who were either newly diagnosed or experiencing relapses of the disease. Participants were randomly assigned in a double-blind manner to receive either rituximab in combination with glucocorticoids or a conventional treatment regimen that involved glucocorticoids alone or in combination with cyclophosphamide for more severe cases.

The primary endpoint of the study was the achievement of remission, defined as a Birmingham Vasculitis Activity Score of 0 alongside a reduced prednisone dosage of 7.5 mg/day or less by day 180. A total of 105 participants were included in the trial. The results showed that 63.5% of those who received rituximab achieved remission compared to 60.4% in the control group, indicating a relative risk of 1.05, with a 95% confidence interval of 0.78 to 1.42 and a p-value of 0.75. These findings suggest no significant difference in the effectiveness of the two treatment strategies.

Additional assessments conducted at day 360 of the study revealed similar outcomes, with the mean remission duration reported as 48.5 weeks for the rituximab group and 49.1 weeks for the conventional strategy cohort. The analysis also showed no significant differences in the average daily glucocorticoid dosage between the two groups, nor were there notable variations in the incidence of adverse events.

In light of these findings, the authors of the study have revised the role of rituximab in the management of EGPA. The results imply that while rituximab may still be used in certain scenarios, it does not offer any additional benefits over established treatment protocols.

For further details, refer to the original study: Benjamin Terrier et al, "Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis," Annals of Internal Medicine, DOI: 10.7326/ANNALS-24-03947.